A Phase 3 interventional study of AIN457 and Placebo in Non-infectious Uveitis, sponsored by Novartis Pharmaceuticals. Terminated at 35 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-14.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Uveitis, Intermediate with a site in United States — 2 open to participants now, 5 under way, 1 of them phase 3. Uveitis, Intermediate · United States.
Among the 44 studies in Uveitis, Intermediate with a site in United States, this one is the 13th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2010, is one of 15 in phase 3, and was the 14th registered.
56 studies on the registry are indexed under Uveitis, Intermediate; 2 are open to participants now.
Browse Uveitis, Intermediate studies →2 of the 44 studies in Uveitis, Intermediate with a site in United States are open now. Recruiting first, the newest first:
Massachusetts Eye Research and Surgery Institution · Sites in United States
Ages 18+ · Healthy volunteers
Nisha Acharya · Sites in United States, Italy, United Kingdom
Ages 2+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1 Uveitis, Intermediate study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 16 · Phase 4 6
First in 1998; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 36 across 42 interventional studies indexed under Uveitis, Intermediate.
Median enrollment 30 across the 39 interventional studies, 60 across the 5 observational. Of the 36 that completed or were terminated, 19 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 7 studies filed under Uveitis, Intermediate — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 44 studies in Uveitis, Intermediate with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
AIN457 300 mg subcutaneous (s.c.) weekly for 3 weeks followed by AIN457 300 mg s.c. every 2 weeks
Drug: AIN457
AIN457 300 mg s.c. at baseline for Week 2 followed by AIN457 300 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
Drug: AIN457
AIN457 150 mg s.c. and placebo s.c. at Baseline and Week 2 followed by AIN457 150 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
Drug: AIN457
Placebo s.c. every 2 weeks
Drug: Placebo
AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
Matching placebo to AIN457
The Time to the First Recurrence in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline
Kaplan-Meier estimates for the time to the first recurrence in any eye of active intermediate, posterior, or panuveitis from baseline defined by either: ≥ 2 step increase in vitreous haze with or without an increase in anterior chamber cell grade or decrease in best corrected visual acuity, core and extension
Time frame: Baseline to 52 weeks
Change in Vitreous Haze Score for the Study Eye From Baseline to the Highest Post-baseline Value
The changes in steps (0, 1, or \>= 2) from previous visit for vitreous haze, where the score is evaluated based on NEI Vitreous Haze Grading Scale (0 -4). Vitreous haze was recorded as 0-clear; to 4+ as dense opacity obscuring the optic nerve head. A 1 step increase is defined as any of the following changes: 0-1, 0.5-1, 1-2, 2-3, 3-4. A 2 step increase is defined as any of the following changes: 0-2, 0.5-2, 1-3, 2-4. A recurrent episode of active intermediate, posterior or panuveitis was considered to be resolved, if the eye returns and maintains in a quiescent state (\<1+ anterior chamber cell grade and \<1+ vitreous haze) for at least 2 weeks
Time frame: Baseline to 52 weeks
Mean Change in Best Corrected Visual Acuity From Baseline, Core and Extension
The Best Corrected Visual Acuity (BCVA) is tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity (VA) testing protocol. VA measurements are taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score is calculated using the BCVA worksheet 0-100 letter score
Time frame: Baseline to 52 weeks
Number of Participants With First Recurrence in in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline During the Core and Extension Studies
Evaluation of recurrence until resolution is ascertained, based on the first criteria (a \>2 step increase in vitreous haze with or without an increase in anterior chamber cell grade in either eye). A 2 step increase is defined as any of the following changes: 0-2, 0.5-2, 1-3, 2-4
Time frame: Baseline to 52 weeks
Composite Immunosuppressive Medication Score From Baseline to Week 52, Core and Extension
IMS is a combined, single numeric score derived on the basis of the total daily dose of specific immunosuppressive agents per unit body weight, ranged on a scale from 0 to 9 for the total daily dose in milligrams per kilogram. The total IMS is the sum of the scores derived for the agents included into the score. The treatment groups will be compared using an analysis of covariance with treatment, region, and baseline IMS as covariate. The total IMS is the sum of scores derived from the agents included into the score, and ranged from 0 to 55. Treatment groups compared using analysis of covariance with treatment \& baseline IMS as covariate, where the lower IMS showed better clinical outcome.
Time frame: Baseline to 52 weeks
Between August 2010 and March 2011, 70 patients were enrolled from 51 centers in 9 countries (United States, Germany, Switzerland, India, Spain, United Kingdom, Israel, Brazil, Italy). Recruitment was stopped due to study termination, therefore 16 out of 86 patients signed informed consent while being in core study were not enrolled into extension
| Milestone | AIN457 300mg Every 2 Weeks | AIN457 300 mg Every 4 Weeks | AIN457 150 mg Every 4 Weeks | Placebo |
|---|---|---|---|---|
| Started | 29 | 31 | 31 | 34 |
| Completed | 21 | 20 | 24 | 27 |
| Not completed | 8 | 11 | 7 | 7 |
| Withdrew: Adverse event | 2 | 2 | 1 | 1 |
| Withdrew: Subject withdrew consent | 0 | 3 | 1 | 1 |
| Withdrew: Abnormal test procedure result | 0 | 0 | 1 | 0 |
| Withdrew: Administrative reasons | 5 | 6 | 4 | 4 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 1 |
| Milestone | AIN457 300mg Every 2 Weeks | AIN457 300 mg Every 4 Weeks | AIN457 150 mg Every 4 Weeks | Placebo |
|---|---|---|---|---|
| Started | 17 | 16 | 16 | 21 |
| Completed | 3 | 0 | 1 | 1 |
| Not completed | 14 | 16 | 15 | 20 |
| Withdrew: Aministrative problems | 13 | 15 | 14 | 18 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Unsatisfactory therapeutic effect | 1 | 0 | 1 | 1 |
| Withdrew: Subject withdrew consent | 0 | 1 | 0 | 0 |
Kaplan-Meier estimates for the time to the first recurrence in any eye of active intermediate, posterior, or panuveitis from baseline defined by either: ≥ 2 step increase in vitreous haze with or without an increase in anterior chamber cell grade or decrease in best corrected visual acuity, core and extension
| Days | AIN457 300mg Every 2 Weeks | AIN457 300 mg Every 4 Weeks | AIN457 150 mg Every 4 Weeks | Placebo |
|---|---|---|---|---|
| The Time to the First Recurrence in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline | NA (265.0 to NA) | NA (87.0 to NA) | NA (178.0 to NA) | NA (228.0 to NA) |
The changes in steps (0, 1, or \>= 2) from previous visit for vitreous haze, where the score is evaluated based on NEI Vitreous Haze Grading Scale (0 -4). Vitreous haze was recorded as 0-clear; to 4+ as dense opacity obscuring the optic nerve head. A 1 step increase is defined as any of the following changes: 0-1, 0.5-1, 1-2, 2-3, 3-4. A 2 step increase is defined as any of the following changes: 0-2, 0.5-2, 1-3, 2-4. A recurrent episode of active intermediate, posterior or panuveitis was considered to be resolved, if the eye returns and maintains in a quiescent state (\<1+ anterior chamber cell grade and \<1+ vitreous haze) for at least 2 weeks
| Number of participants | AIN457 300mg Every 2 Weeks | AIN457 300 mg Every 4 Weeks | AIN457 150 mg Every 4 Weeks | Placebo |
|---|---|---|---|---|
| 2 or more steps increase | 4 | 2 | 1 | 2 |
| 1 step increase | 4 | 8 | 7 | 11 |
| No changes | 21 | 21 | 23 | 20 |
| 1 step decrease | 0 | 0 | 0 | 0 |
| 2 or more steps decrease | 0 | 0 | 0 | 0 |
The Best Corrected Visual Acuity (BCVA) is tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity (VA) testing protocol. VA measurements are taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score is calculated using the BCVA worksheet 0-100 letter score
| Letters | AIN457 300mg Every 2 Weeks | AIN457 300 mg Every 4 Weeks | AIN457 150 mg Every 4 Weeks | Placebo |
|---|---|---|---|---|
| Mean Change in Best Corrected Visual Acuity From Baseline, Core and Extension | 9 ± 4.36 | — | 16 ± NA | 5 ± NA |
Evaluation of recurrence until resolution is ascertained, based on the first criteria (a \>2 step increase in vitreous haze with or without an increase in anterior chamber cell grade in either eye). A 2 step increase is defined as any of the following changes: 0-2, 0.5-2, 1-3, 2-4
| Number of participants | AIN457 300mg Every 2 Weeks | AIN457 300 mg Every 4 Weeks | AIN457 150 mg Every 4 Weeks | Placebo |
|---|---|---|---|---|
| Patients with recurrence | 8 | 11 | 10 | 11 |
| Patients with only vitreous haze criterion | 2 | 3 | 4 | 2 |
| Patients with only visual acuity criterion | 5 | 8 | 6 | 9 |
| Both criteria at the same time | 1 | 0 | 0 | 0 |
IMS is a combined, single numeric score derived on the basis of the total daily dose of specific immunosuppressive agents per unit body weight, ranged on a scale from 0 to 9 for the total daily dose in milligrams per kilogram. The total IMS is the sum of the scores derived for the agents included into the score. The treatment groups will be compared using an analysis of covariance with treatment, region, and baseline IMS as covariate. The total IMS is the sum of scores derived from the agents included into the score, and ranged from 0 to 55. Treatment groups compared using analysis of covariance with treatment \& baseline IMS as covariate, where the lower IMS showed better clinical outcome.
| Units on a scale | AIN457 300mg Every 2 Weeks | AIN457 300 mg Every 4 Weeks | AIN457 150 mg Every 4 Weeks | Placebo |
|---|---|---|---|---|
| Composite Immunosuppressive Medication Score From Baseline to Week 52, Core and Extension | -5.67 ± 4.163 | — | -1 ± NA | -1 ± NA |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AIN457 300mg Every 2 Weeks | — | 4/29 (13.8%) | 20/29 (69%) |
| AIN457 300mg Every 4 Weeks | — | 1/31 (3.2%) | 19/31 (61.3%) |
| AIN457 150mg Every 4 Weeks | — | 1/31 (3.2%) | 22/31 (71%) |
| Placebo Every 2 Weeks | — | 2/33 (6.1%) | 22/33 (66.7%) |
| Event | AIN457 300mg Every 2 Weeks | AIN457 300mg Every 4 Weeks | AIN457 150mg Every 4 Weeks | Placebo Every 2 Weeks |
|---|---|---|---|---|
| Uveitis (Study eye)Eye disorders | 1/29 | 0/31 | 1/31 | 0/33 |
| Lower respiratory tract infectionInfections and infestations | 1/29 | 0/31 | 0/31 | 0/33 |
| Joint dislocationInjury, poisoning and procedural complications | 1/29 | 0/31 | 0/31 | 0/33 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/29 | 0/31 | 0/31 | 0/33 |
| Uveitis (Fellow eye)Eye disorders | 0/29 | 0/31 | 1/31 | 0/33 |
| Mononeuropathy multiplexNervous system disorders | 0/29 | 1/31 | 0/31 | 0/33 |
| SarcoidosisImmune system disorders | 0/29 | 0/31 | 0/31 | 1/33 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/29 | 0/31 | 0/31 | 1/33 |
| Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/29 | 0/31 | 0/31 | 1/33 |
| Seborrhoeic keratosisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/29 | 0/31 | 0/31 | 1/33 |
| Event | AIN457 300mg Every 2 Weeks | AIN457 300mg Every 4 Weeks | AIN457 150mg Every 4 Weeks | Placebo Every 2 Weeks |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/29 | 4/31 | 4/31 | 5/33 |
| HeadacheNervous system disorders | 6/29 | 4/31 | 2/31 | 0/33 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/29 | 4/31 | 3/31 | 2/33 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/29 | 1/31 | 4/31 | 0/33 |
| NauseaGastrointestinal disorders | 0/29 | 2/31 | 2/31 | 4/33 |
| DizzinessNervous system disorders | 0/29 | 3/31 | 1/31 | 4/33 |
| InfluenzaInfections and infestations | 3/29 | 3/31 | 2/31 | 0/33 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/29 | 0/31 | 3/31 | 2/33 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/29 | 3/31 | 1/31 | 2/33 |
| PruritusSkin and subcutaneous tissue disorders | 0/29 | 3/31 | 0/31 | 0/33 |
| Age, Continuous(Years) | AIN457 300mg Every 2 Weeks | AIN457 300 mg Every 4 Weeks | AIN457 150 mg Every 4 Weeks | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 46.2 ± 14.29 | 49.2 ± 11.14 | 47.7 ± 13.50 | 47.3 ± 15.46 | 47.6 ± 13.60 |
| Sex: Female, Male(Participants) | AIN457 300mg Every 2 Weeks | AIN457 300 mg Every 4 Weeks | AIN457 150 mg Every 4 Weeks | Placebo | Total |
|---|---|---|---|---|---|
| Female | 17 | 16 | 20 | 18 | 71 |
| Male | 12 | 15 | 11 | 16 | 54 |
The record gives a start of Aug 2010, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 4 years 6 months after primary completion. A results delay was requested in Jul 2013.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab